A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.
Study Details
Study Description
Brief Summary
A first-in-human clinical trial to test the investigational treatment ONCT-534 in participants with metastatic castration-resistant prostate cancer. The main questions it aims to answer are:
-
What are the most tolerable doses of ONCT-534? (Phase 1)
-
Does ONCT-534 have anti-tumor activity at tolerable doses? (Phase 2)
This is a dose escalation and expansion study where participants will receive daily oral doses of ONCT-534.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1/Phase 2 |
Detailed Description
This is a Phase 1/2 multi-center study to investigate the safety, tolerability, and anti-tumor acitivity of ONCT-534 in patients with relapsed or refractory metastatic castration-resistant prostate cancer. The study consists of 2 phases: a Phase 1 Dose Escalation and a Phase 2 Dose Expansion.
-
During the dose escalation in Phase 1 a group of participants will be assigned a certain dose level. Once the dose level is considered safe, the next group will be assigned a higher dose level. The dose level may be raised or lowered depending on any safety events that occur throughout Phase 1. There will be approximately 27 participants enrolled in Phase 1. At the end of Phase 1, two dose levels will be chosen to be tested in Phase 2.
-
During Phase 2, participants will be randomly assigned to 1 of the 2 dose levels chose in Phase 1. Approximately 16 participants will be enrolled in each of the 2 dose level groups, for a total of 32 participants.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Dose Level 1: 40mg 40mg of single agent ONCT-534 to be administered daily in oral tablets |
Drug: ONCT-534
ONCT-534 is a dual-action androgen receptor inhibitor (DAARI) with a novel mechanism of action that includes inhibition of AR function and degradation of the AR protein mediated by interaction with the N-terminal domain (NTD) of the AR. ONCT-534 has demonstrated preclinical activity in prostate cancer models against both unmutated androgen receptor (AR), and against multiple forms of AR alteration, including those with AR amplification, mutations in the AR ligand binding domain (LBD), and splice variants with loss of the AR LBD.
Other Names:
|
| Experimental: Dose Level 2: 80mg 80mg of single agent ONCT-534 to be administered daily in oral tablets |
Drug: ONCT-534
ONCT-534 is a dual-action androgen receptor inhibitor (DAARI) with a novel mechanism of action that includes inhibition of AR function and degradation of the AR protein mediated by interaction with the N-terminal domain (NTD) of the AR. ONCT-534 has demonstrated preclinical activity in prostate cancer models against both unmutated androgen receptor (AR), and against multiple forms of AR alteration, including those with AR amplification, mutations in the AR ligand binding domain (LBD), and splice variants with loss of the AR LBD.
Other Names:
|
| Experimental: Dose Level 3: 160mg 160mg of single agent ONCT-534 to be administered daily in oral tablets |
Drug: ONCT-534
ONCT-534 is a dual-action androgen receptor inhibitor (DAARI) with a novel mechanism of action that includes inhibition of AR function and degradation of the AR protein mediated by interaction with the N-terminal domain (NTD) of the AR. ONCT-534 has demonstrated preclinical activity in prostate cancer models against both unmutated androgen receptor (AR), and against multiple forms of AR alteration, including those with AR amplification, mutations in the AR ligand binding domain (LBD), and splice variants with loss of the AR LBD.
Other Names:
|
| Experimental: Dose Level 4: 300mg 300mg of single agent ONCT-534 to be administered daily in oral tablets |
Drug: ONCT-534
ONCT-534 is a dual-action androgen receptor inhibitor (DAARI) with a novel mechanism of action that includes inhibition of AR function and degradation of the AR protein mediated by interaction with the N-terminal domain (NTD) of the AR. ONCT-534 has demonstrated preclinical activity in prostate cancer models against both unmutated androgen receptor (AR), and against multiple forms of AR alteration, including those with AR amplification, mutations in the AR ligand binding domain (LBD), and splice variants with loss of the AR LBD.
Other Names:
|
| Experimental: Dose Level 5: 600mg 600mg of single agent ONCT-534 to be administered daily in oral tablets |
Drug: ONCT-534
ONCT-534 is a dual-action androgen receptor inhibitor (DAARI) with a novel mechanism of action that includes inhibition of AR function and degradation of the AR protein mediated by interaction with the N-terminal domain (NTD) of the AR. ONCT-534 has demonstrated preclinical activity in prostate cancer models against both unmutated androgen receptor (AR), and against multiple forms of AR alteration, including those with AR amplification, mutations in the AR ligand binding domain (LBD), and splice variants with loss of the AR LBD.
Other Names:
|
| Experimental: Dose Level #1 Recommended Phase 2 dose level #1 of single agent ONCT-534 to be administered daily in oral tablets |
Drug: ONCT-534
ONCT-534 is a dual-action androgen receptor inhibitor (DAARI) with a novel mechanism of action that includes inhibition of AR function and degradation of the AR protein mediated by interaction with the N-terminal domain (NTD) of the AR. ONCT-534 has demonstrated preclinical activity in prostate cancer models against both unmutated androgen receptor (AR), and against multiple forms of AR alteration, including those with AR amplification, mutations in the AR ligand binding domain (LBD), and splice variants with loss of the AR LBD.
Other Names:
|
| Experimental: Dose Level #2 Recommended Phase 2 dose level #2 of single agent ONCT-534 to be administered daily in oral tablets |
Drug: ONCT-534
ONCT-534 is a dual-action androgen receptor inhibitor (DAARI) with a novel mechanism of action that includes inhibition of AR function and degradation of the AR protein mediated by interaction with the N-terminal domain (NTD) of the AR. ONCT-534 has demonstrated preclinical activity in prostate cancer models against both unmutated androgen receptor (AR), and against multiple forms of AR alteration, including those with AR amplification, mutations in the AR ligand binding domain (LBD), and splice variants with loss of the AR LBD.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Determination of the MTD of ONCT-534 [28 Days]
MTD will be determined using incidence of DLTs
- Assess safety and tolerability of ONCT-534 [108 weeks]
Incidence of AEs and SAEs
- Reduction of PSA by more than 50% [108 Weeks]
Proportion of patients who achieve PSA50
- Time to reduction of PSA by more than 50% [108 Weeks]
Time in months to achieve PSA50
- Reduction of PSA by more than 90% [108 Weeks]
Proportion of patients who achieve PSA590
- Time to reduction of PSA by more than 90% [108 Weeks]
Time in months to achieve PSA90
- Objective Response Rate [108 Weeks]
Proportion of subjects with a response to treatment (CR or PR) based on PCWG 3 and RECIST 1.1
- Complete Response Rate [108 Weeks]
Proportion of subjects with CR based on PCWG 3 and RECIST 1.1
- Duration of Response [108 Weeks]
Time in months between initial response (CR or PR) and the date of first disease progression, relapse or death.
- Progression Free Survival [108 Weeks]
Time in months between first study treatment dose date and date of first disease progression based on PCWG 3 and RECIST 1.1 or death.
Secondary Outcome Measures
- Assess Maximum Plasma Concentration (Cmax) of ONCT-534 [12 Weeks]
The peak concentration of ONCT-534 in the body will be reported using descriptive statistics
- Assess Area Under the Curve (AUC) of ONCT-534 [12 Weeks]
AUC will be reported using descriptive statistics
- Correlate anti-tumor activity of ONCT-534 with AR phenotype [108 Weeks]
Correlation analyses will assess associations between objective responses and changes in AR levels or AR phenotype
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Subject is ≥18 years of age
-
Subject has histologically documented metastatic adenocarcinoma of the prostate confirmed by biopsy without neuroendocrine differentiation or small cell features.
-
Subjects has a history of metastatic CRPC.
-
Subject has R/R disease following treatment with at least one next-generation AR-signaling inhibitor.
-
Subject has at least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria or evaluable bony disease. Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy.
-
Subject has an Eastern Cooperative Oncology Group performance status of 0 or 1, and life expectancy of ≥ 6 months.
-
Subject agrees to take or continue luteinizing hormone-releasing hormone agonist or antagonist therapy or has undergone bilateral orchiectomy.
-
At least 2 weeks or five half-lives have elapsed, whichever is earliest, since last systemic therapy, including taxanes or other chemotherapy. At least one month has elapsed since systemic therapy with radionuclide pharmaceutical agents
-
Subject has evidence of disease progression on or after their most recent systemic treatment
-
Subject has a PSA level ≥ 10 ng/mL, or ≥ 2 ng/mL and ≥ 50% increase from nadir on prior therapy, whichever is lowest.
-
Subject has serum testosterone < 50 ng/dL.
-
Subject has adequate renal, hepatic, and pulmonary function
-
Subject is committed to practice true abstinence, or use a highly effective method of contraception with any female partner of childbearing potential unless documented to be surgically sterile (i.e., vasectomy or bilateral orchiectomy) and to not make semen donations during the study and for 3 months after the last dose of study drug.
Exclusion Criteria:
-
Subject has small cell prostate cancer or neuroendocrine disease histology, including mixed histology.
-
Subject has metastases to the brain or central nervous system
-
Subject is receiving concurrent anti-cancer therapy (chemotherapy, immunotherapy, biologic therapy) except for ongoing androgen inhibiting therapy such as luteinizing hormone-releasing hormone (LHRH) agonists. Supportive non-cancer directed therapies such as bisphosphonates or denosumab are allowed.
-
Subjects taking a strong inhibitor of CYP3A4 or a substrate of CYP2C9 or CYP2C19
-
Subject had major surgery within 30 days prior to start of study drug.
-
Subject has current, untreated pathologic long-bone fractures(s), or risk of imminent pathologic fracture(s).
-
Subject has current or imminent spinal cord compression.
-
Subject has an active seizure disorder or a history of seizure disorder.
-
Subject has evidence of active human immunodeficiency virus infection, hepatitis B virus (HBV), or hepatitis C virus (HCV)
-
Subject has any other serious illness or medical condition in the opinion of the Investigator
-
Subject has abnormal electrocardiograms (ECGs) that are clinically significant, including average QTcF > 450 ms, or a history of Torsade de Pointes.
-
Subject has any infection requiring parenteral antibiotic therapy or causing fever (temperature >100.5°F or 38.1°C) within 1 week prior to first dose.
-
Clinically significant other malignancy with the potential to confound study assessments, with the exception of e.g., treated cutaneous squamous cell and basal carcinomas, non-muscle invasive bladder cancer, Rai Stage 0 CLL, and adequately treated Stage 1 to 2 non-cutaneous malignancy in remission for 5 years.
-
Subject is unable to comply with the protocol and/or not willing or not available for follow-up assessments
-
Subject has any medical intervention or other condition which could compromise adherence with study requirements or otherwise compromise the study's objectives.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Oncternal Therapeutics, Inc
Investigators
- Study Director: Salim Yazji, MD, Oncternal Therapeutics
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ONCT-534-101